# FORM D

Notice of Exempt Offering of Securities

ببلائده واوار واسور بموارية

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C.

OMB APPROVAL
OMB Number: 3235-0076
Expires: August 31, 2015
Estimated Average burden hours per response: 4.0

T. Issuer's identity			
CIK (Filer ID Number)	Previous Name(s)	☐ None	Entity Type
0001498382	Berry Only Inc.		Corporation
Name of Issuer	7		C Limited Partnership
DelMar Pharmaceuticals, Inc.			C Limited Liability Company
Jurisdiction of Incorporation/Organization			C General Partnership
NEVADA			C Business Trust
Year of Incorporation/Organizatio	on		C Other
Over Five Years Ago			<u></u>
© Within Last Five Years (Specify Year)	2009		

(Specify Year)

• Yet to Be Formed

# 2. Principal Place of Business and Contact Information

Name of Issuer			
DelMar Pharmaceuticals, Inc.			
Street Address 1		Street Address 2	
SUITE 720-999 WEST BROAD	DWAY		
City	State/Province/Country	y ZIP/Postal Code	Phone No. of Issuer
VANCOUVER	BRITISH COLUMB CANADA	IA, V5Z 1K5	(604) 629-5989

# 3. Related Persons

Last Name	First Name		Middle Name
Bacha	Jeffrey		
Street Address 1		Street Address 2	
Suite 720-999 West Broadway			
City	State/Province/C	ountry	ZIP/Postal Code
Vancouver BRITISH COLU		LUMBIA, CANADA	V5Z 1K5
Relationship: 🔽 Execu	tive Officer	Director	Promoter
Clarification of Response (if Necessar	y)		

T.-14. C----

-

## C Agriculture

## Banking & Financial Services

C Commercial Banking

- C Insurance
- C Investing
- C Investment Banking
- C Pooled Investment Fund
- Other Banking & Financial O Services

#### C Business Services

#### Energy

- C Coal Mining
- C Electric Utilities
- C Energy Conservation
- C Environmental Services
- C Oil & Gas
- C Other Energy

## 5. Issuer Size

### Health Care

C Manufacturing

**Real Estate** 

C

C

C

C

C Commercial

Construction

Residential

**REITS & Finance** 

Other Real Estate

- C Biotechnology
- C Health InsuranceC Hospitals & Phys
- C Hospitals & PhysiciansC Pharmaceuticals
- O Other Health Care
- our munin our

## C Retailing

#### C Restaurants

#### Technology

- C Computers
- C Telecommunications
- C Other Technology

#### Travel

- C Airlines & Airports
- C Lodging & Conventions
- C Tourism & Travel Services
- C Other Travel

#### C Other

**Revenue Range** Aggregate Net Asset Value Range  $\mathbf{\Theta}$ No Revenues C No Aggregate Net Asset Value C \$1 - \$1,000,000 C \$1 - \$5,000,000 C 0 \$1,000,001 - \$5,000,000 \$5,000,001 - \$25,000,000 C \$5,000,001 - \$25,000,000 0 \$25,000,001 - \$50,000,000 C \$25,000,001 - \$100,000,000 C \$50,000,001 - \$100,000,000 C C Over \$100,000,000 Over \$100,000,000 C C Decline to Disclose **Decline to Disclose** C C Not Applicable Not Applicable

# 6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)

Rule 504(b)(1) (not (i), (ii) or (iii))	Rule 505	
Rule 504 (b)(1)(i)	<b>Rule 506(b)</b>	
Rule 504 (b)(1)(ii)	Rule 506(c)	
Rule 504 (b)(1)(iii)	Securities Act Section 40	(a)(5)
	Investment Company A	ct Section 3(c)

# 7. Type of Filing

New Notice Date of First Sale

2013-01-25

First Sale Yet to Occur

Amendment

8. Duration of Offering



# 9. Type(s) of Securities Offered (select all that apply)

- Pooled Investment Fund Interests
- Equity Tenant-in-Common Securities Debt
- Mineral Property Securities
- Option, Warrant or Other Right to Acquire Another Security
- Security to be Acquired Upon Exercise of Option, Warrant or C Other (describe) Other Right to Acquire Security

# 10. Business Combination Transaction

Is this offering being made in connection with a business combination Yes C No transaction, such as a merger, acquisition or exchange offer?

Clarification of Response (if Necessary)

# 11. Minimum Investment

Minimum investment accepted from any outside investor

USD

12. Sales Compensation	
Recipient	Recipient CRD Number
Charles Vista, LLC	132650
(Associated) Broker or Dealer 🔽 None	(Associated) Broker or Dealer CRD Number
Street Address 1	Street Address 2
201 Edward Curry Avenue	Suite 103
City Stat	te/Province/Country ZIP/Postal Code
Staten Island	EW YORK 10314
State(s) of Solicitation	preign/Non-US

\$ 5000

ALABAMA
ALASKA
CALIFORNIA
COLORADO
CONNECTICUT
FLORIDA
ILLINOIS
INDIANA
LOUISIANA
MARYLAND
MASSACHUSETTS
MICHIGAN
MINNESOTA
NEW JERSEY
NEW YORK
оніо

TEXAS
UTAH
WASHINGTON

# 13. Offering and Sales Amounts

Total Offering Amount	\$ 10000000	USD	Indefinite
Total Amount Sold	\$ 6887450	USD	
Total Remaining to be Sold	\$ 3112550	USD	🗖 Indefinite

Clarification of Response (if Necessary)

14. Investors

(

Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors,

Number of such non-accredited investors who already have invested in the offering

Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering:

# 15. Sales Commissions & Finders' Fees Expenses

Provide separately the amounts of sales commissions and finders' fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.

48

Sales Commissions \$	895368	USD	Estimate
Finders' Fees \$	0	USD	Estimate
Clarification of Response (if Necessary)			
10% Placement Agent Fee and 3%	non-accountable expense.		

# 16. Use of Proceeds

Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.

	\$ 144000	USD	Estimate
Clarification of Response (if Necessary)			
Mr. Bacha, CEO, is under contract with the corporation and receives remuneration of \$12,000 per month for services.			
Signature and Submission			

Please verify the information you have entered and review the Terms of Submission

#### below before signing and clicking SUBMIT below to file this notice.

#### Terms of Submission

In submitting this notice, each Issuer named above is:

- Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, the information furnished to offerees.
- Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the Issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against it in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of: (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
- Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Regulation D for one of the reasons stated in Rule 505(b)(2)(iii) or Rule 506(d).

Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

Issuer	Signature	Name of Signer	Title	Date
DelMar Pharmaceuticals, Inc.	/s/ Jeffrey Bacha	Jeffrey Bacha	Chief Executive Officer	2013-02-07